We are committed to finding a cure for WM.

Abstract: BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia

Go to website – http://pipelinereview.com/index.php/2017012563690/Small-Molecules/BeiGene-Initiates-Global-Phase-III-Trial-of-the-BTK-Inhibitor-BGB-3111-in-Waldenstroms-Macroglobulinemia.html

PDF – BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia | Small Molecules | News Channels

BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s… Continue reading

Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management

http://onlinelibrary.wiley.com/doi/10.1002/ajh.24557/full

Get the PDF Here –

Gertz-2017-Annual Clinical Updates in Hematological Malignancies

Abstract

Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity.

Diagnosis: Presence… Continue reading

Mayo Clinic Update on Diagnosis and Treatment of WM

 

 

 

 

 

This open source article was recently published in the American Journal of Hematology. 

Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management

Authors

  • Morie A. Gertz
  • First published: 

 

WEBSITE

PDF